www.fool.com

www.fool.com
Share

www.fool.com

 •  January 7

Get ready for a wave of new blockbuster drugs in 2018. At least nine new drugs are expected to launch this year that have the potential for sales to top $1 billion by 2022, according to market research firm EvaluatePharma. Gilead Sciences (NASDAQ:GILD), Novo Nordisk (NYSE:NVO), Incyte (NASDAQ:INCY), AbbVie (NYSE:ABBV), and Celgene (NASDAQ:CELG)...

www.fool.com

 •  October 8, 2017

Diabetes is often referred to in the medical community as the "silent killer." Affecting more than 30 million people in the U.S. (9.4% of the population), diabetes was listed the cause of death for nearly 80,000 people in 2016, according to the Centers for Disease Control and Prevention. Its comorbidities, such as hypertension, heart disease, and...

www.fool.com

 •  October 3, 2017

The cost of clinical trials jumps significantly when drugmakers move from phase 1 to phase 2 and phase 2 to phase 3. To reduce research and development costs, drugmakers are increasingly embracing exploratory interim trials. But that's not the only reason why the biopharma industry does them. In this clip from The Motley Fool's Industry Focus:...

www.fool.com

 •  September 28, 2017

Biosimilars that are as safe and effective as expensive brand-name biologics could significantly reduce drug prices and healthcare spending, but only if they win support from insurers. Unfortunately, drugmakers like Johnson & Johnson (NYSE:JNJ) may be employing tactics to keep that from happening. In this episode of the Motley Fool's Industry...

www.fool.com

 •  September 26, 2017

Drugmakers are increasingly embracing new tactics to protect billions of dollars in sales from generic competition. These strategies often involve patent trials, but that's not the only way companies are waylaying generic drugmakers. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd...

www.fool.com

 •  August 5, 2017

The more than 50-year war that's been waged by the U.S. against tobacco companies has been working. According to the latest statistics from the Centers for Disease Control and Prevention (CDC), an estimated 15.1% of U.S. adults (36.5 million) aged 18 and older were smoking cigarettes as of 2015. That's down from 20.9% of all U.S. adults back in...

www.fool.com

 •  July 16, 2017

Stocks that are worth buying and holding for exceptionally long periods of time are far less common than most investors may think. Changes in underlying market conditions, after all, can knock even top performers off their perches. Even so, our investors think that Pfizer (NYSE:PFE), Activision Blizzard (NASDAQ:ATVI), and Berkshire Hathaway...

www.fool.com

 •  June 25, 2017

The U.S. Food and Drug Administration (FDA) is tasked with an inglorious job. It digs through hundreds, if not thousands, of pages of clinical trial data to determine if an experimental drug or medical device effectively reaches its treatment goal without outweighing the risks involved with taking or using it. The FDA has formally done this task...

www.fool.com

 •  June 24, 2017

Portola Pharmaceuticals' (NASDAQ:PTLA) investors who stuck with it after stumbles caused share prices to crash last year are feeling a bit better about their position today. On Friday, the Food and Drug Administration approved the company's first drug, Bevyxxa, and that news caused shares to spike over 45% by late in the trading day. Because Bevyxx...

www.fool.com

 •  June 6, 2017

Pharmaceutical giant Merck (NYSE:MRK) has been on a roll recently, with anti-cancer drug Keytruda winning approval for multiple manifestations of the disease. An approval for one particular indication last month continues the good news for the drug and has broader implications for the drug industry and personalized medicine. An unprecedented...